By integrating the mechanistism score with tumor stage, we developed a clinical scoring model based on TP63 and SLC7A5, employing nomograms for the prediction of one-year, three-year, and five-year survival rates in patients (Figure 4H). This evidence concerns the gene SLC7A5 and neoplasm.